Skip to main content

Table 4 Number and percentage of patients using each healthcare resource during 2 L treatment

From: Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer

Resource, n (%)a

Australia (N = 34)

Canada (N = 100)

Italy (N = 84)

UK (N = 62)

Overall (N = 280)

Hospitalization/inpatient stay

11 (32.4%)

30 (30.0%)

14 (16.7%)

20 (32.3%)

75 (26.8%)

ICU stay

-

2 (2.0%)

-

-

2 (0.7%)

Emergency room visit

3 (8.8%)

19 (19.0%)

2 (2.4%)

7 (11.3%)

31 (11.1%)

Outpatient (visit for follow-up)

21 (61.8%)

27 (27.0%)

51 (60.7%)

50 (80.6%)

149 (53.2%)

Concomitant medication

30 (88.2%)

91 (91.0%)

84 (100.0%)

60 (96.8%)

265 (94.6%)

Laboratory tests

27 (79.4%)

95 (95.0%)

78 (92.9%)

61 (98.4%)

261 (93.2%)

 Blood cell count

27 (79.4%)

94 (94.0%)

78 (92.9%)

61 (98.4%)

260 (92.9%)

 Biochemistry test

27 (79.4%)

92 (92.0%)

78 (92.9%)

61 (98.4%)

258 (92.1%)

 Liver function test

27 (79.4%)

92 (92.0%)

78 (92.9%)

57 (91.9%)

254 (90.7%)

 Renal function test

27 (79.4%)

94 (94.0%)

77 (91.7%)

56 (90.3%)

254 (90.7%)

 Blood pressure reading

26 (76.5%)

53 (53.0%)

58 (69.0%)

49 (79.0%)

186 (66.4%)

 Electrocardiogram

7 (20.6%)

18 (18.0%)

21 (25.0%)

14 (22.6%)

60 (21.4%)

Imaging tests

26 (76.5%)

78 (78.0%)

37 (44.0%)

56 (90.3%)

197 (70.4%)

X-ray

11 (32.4%)

44 (44.0%)

17 (20.2%)

10 (16.1%)

82 (29.3%)

Ultrasound

8 (23.5%)

24 (24.0%)

5 (6.0%)

9 (14.5%)

46 (16.4%)

 CT

25 (73.5%)

60 (60.0%)

27 (32.1%)

54 (87.1%)

166 (59.3%)

 MRI scan

1 (2.9%)

5 (5.0%)

1 (1.2%)

2 (3.2%)

9 (3.2%)

 PET scan

-

1 (1.0%)

-

1 (1.6%)

2 (0.7%)

 Fluorodeoxyglucose-PET-CT scan

5 (14.7%)

2 (2.0%)

3 (3.6%)

1 (1.6%)

11 (3.9%)

 Endoscopy

2 (5.9%)

7 (7.0%)

2 (2.4%)

5 (8.1%)

16 (5.7%)

 Colonoscopy

-

1 (1.0%)

1 (1.2%)

-

2 (0.7%)

  1. a number and percentage of patients for whom the resource has been used; denominator is the total number of patients
  2. CT Computed tomography, ICU intensive care unit, MRI Magnetic resonance imaging, PET Positron emission tomography